Hearing Loss, Intraocular Retinoblastoma
Conditions
Keywords
Hearing Status, 18-529
Brief summary
The purpose of this study is to find out how often hearing loss occurs in patients with retinoblastoma after receiving treatment with intra-arterial carboplatin.
Interventions
DIAGNOSTIC_TESTDistortion product otoacoustic emission measurement (DPOAE)
Hearing will be measured at baseline and 3-9 months after completion of treatment with IA carboplatin chemotherapy.
Sponsors
Memorial Sloan Kettering Cancer Center
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
3 Months to 18 Years
Healthy volunteers
No
Inclusion criteria
* Signed informed consent indicating awareness of the investigational nature of the protocol. * Children with RB aged 3 months and older who are scheduled to receive their first dose of IA carboplatin chemotherapy. * Retinoblastoma is rarely seen in children over 8 years old, however we will not include an upper age range so as not to exclude any possible participants
Exclusion criteria
* Children with known and documented preexisting hearing loss.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Estimate the incidence of hearing loss | 1 year | will be defined as a \>10 db loss from baseline in any frequency, based on the lower threshold of the American Speech and Hearing Associations (ASHA) hearing change criteria. For children unable to cooperate for an audiogram, the DPOAE will be the primary measurement. |
Countries
United States
Outcome results
None listed